Human Clinical Studies
AHCC has been used with great success in cancer patients. Data from the treatment of over 100,000 individuals with various types of cancer have shown AHCC treatment to be of benefit in 60% of cases. (Kenner p. 15) AHCC is particularly effective for liver, lung, stomach, colon, breast, thyroid, ovarian, testicular, tongue, kidney and pancreatic cancers. (Kenner p. 15)
One landmark AHCC trial enrolled 269 patients with liver cancer. Following surgery, about half of the patients took AHCC and about half did not. The results were dramatic: At the end of the ten-year study, only 34.5% of the AHCC patients experienced a recurrence in their cancer, compared with 66.1% of the control group. Similarly, while 46.8% of the patients in the control group had died at the end of ten years, less than half that amount — 20.4% — of those in the AHCC group had. Another study found that AHCC not only prolonged survival of advanced liver cancer patients, it also improved various parameters of quality of life, including mental stability, general physical health status and the ability to have normal activities.
Chemotherapy is fraught with side effects, which range from psychologically distressing to life-threatening. In addition to being able to fight cancer directly, AHCC also alleviates many of the side effects of chemotherapy, including:
- Hair Loss: Doctors noticed that chemotherapy patients taking AHCC did not lose their hair. Subsequently, an in vivo study found that mice treated with AHCC were protected from chemically induced hair loss.
- Nausea: Clinical studies in Korea and Japan have indicated that AHCC remarkably improves symptoms of nausea and vomiting in cancer patients. (Kenner, p. 18)
- Bone Marrow Suppression: Chemotherapy can inhibit bone marrow function, which is life-threatening because the body’s key immune soldiers — the white blood cells — originate in bone marrow. AHCC has been shown to raise the white blood cell count of cancer patients by about 30%. (Kenner, p. 17)
- Liver Damage: One of the major drawbacks of chemotherapy is that it kills healthy cells in addition to cancer cells. An in vivo study found that while rats given chemotherapy experienced large increases in liver enzymes (indicative of liver damage), those given chemotherapy plus AHCC had normal levels. (Kenner, p. 17)
Dr. Fred Pescatore, of the Center for Integrative and Complementary Medicine in New York, has reported that he has achieved marked reductions in the liver enzymes of hepatitis patients through the use of AHCC. This is an important discovery, as high levels of liver enzymes are indicative of liver damage. Dr. Pescatore has also observed massive drops in the viral loads of hepatitis C patients. One case study, a 47 year-old male, had a viral load of 2,498,200 before treatment, which plunged to 499,600 after six months on AHCC — an 80% reduction.
Animal studies confirm AHCC’s liver-protective effect. Rats treated with AHCC and then administered the liver-toxic chemical carbon tetrachloride were spared from its liver-damaging effect. Similarly, rats treated with AHCC and then administered the lethal substance galactosamine had an improved survival rate compared to control rats. (Kenner, p. 19).
B and T cells: Both B cells (which mature in bone marrow) and T cells (which mature in the thymus) are lymphocytes, WBC that are able to recognize previous invaders and destroy them with a specific response